Fatty Acids

fatty acid amide hydrolase ; Homo sapiens







39 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 34756920 Concentration-dependent effects of chlorpyrifos oxon on peroxisome proliferator-activated receptor signaling in MCF-7 cells. 2022 Feb 1
2 34952353 The influence of FAAH genetic variation on physiological, cognitive, and neural signatures of fear acquisition and extinction learning in women with PTSD. 2022 1
3 34983657 Assessment of NSAIDs as potential inhibitors of the fatty acid amide hydrolase I (FAAH-1) using three different primary fatty acid amide substrates in vitro. 2022 Jan 4 1
4 33070154 The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study. 2021 Apr 1
5 33460184 Association of the Fatty Acid Amide Hydrolase C385A Polymorphism With Alcohol Use Severity and Coping Motives in Heavy-Drinking Youth. 2021 Mar 1
6 34827417 The Inhibition of the Degrading Enzyme Fatty Acid Amide Hydrolase Alters the Activity of the Cone System in the Vervet Monkey Retina. 2021 Oct 27 2
7 34959715 Potential of Fatty Acid Amide Hydrolase (FAAH), Monoacylglycerol Lipase (MAGL), and Diacylglycerol Lipase (DAGL) Enzymes as Targets for Obesity Treatment: A Narrative Review. 2021 Dec 17 1
8 31914367 HYPNOTIZABILITY-RELATED FAAH C385A POLYMORPHISM: POSSIBLE ENDOCANNABINOID CONTRIBUTION TO SUGGESTION-INDUCED ANALGESIA. 2020 Jan-Mar 1
9 32041998 The endocannabinoid hydrolase FAAH is an allosteric enzyme. 2020 Feb 10 1
10 32292082 Advances in the discovery of fatty acid amide hydrolase inhibitors: what does the future hold? 2020 Jul 2
11 32732136 Racial and sex differences in the polymorphisms of the endocannabinoid receptor genes in obesity. 2020 Nov 1
12 30739035 Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro. 2019 Apr 1
13 30929760 Microdeletion in a FAAH pseudogene identified in a patient with high anandamide concentrations and pain insensitivity. 2019 Aug 2
14 31117309 Three-Dimensional Quantitative Structure-Activity Relationships (3D-QSAR) on a Series of Piperazine-Carboxamides Fatty Acid Amide Hydrolase (FAAH) Inhibitors as a Useful Tool for the Design of New Cannabinoid Ligands. 2019 May 21 2
15 31921630 Expression and Function of the Endocannabinoid Modulating Enzymes Fatty Acid Amide Hydrolase and N-Acylphosphatidylethanolamine-Specific Phospholipase D in Endometrial Carcinoma. 2019 1
16 26774927 Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies. 2016 Feb 15 1
17 26901181 Discovery of Uracil Derivatives as Potent Inhibitors of Fatty Acid Amide Hydrolase. 2016 Feb 18 2
18 27309570 Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents. 2016 Jul 14 1
19 27790143 A Personal Retrospective: Elevating Anandamide (AEA) by Targeting Fatty Acid Amide Hydrolase (FAAH) and the Fatty Acid Binding Proteins (FABPs). 2016 1
20 27806235 Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase. 2016 Nov 3 1
21 24593280 The effects of obesity, diabetes and metabolic syndrome on the hydrolytic enzymes of the endocannabinoid system in animal and human adipocytes. 2014 Mar 4 1
22 24705380 Inhibition of fatty acid binding proteins elevates brain anandamide levels and produces analgesia. 2014 1
23 23344792 The interaction of fatty acid amide hydrolase (FAAH) inhibitors with an anandamide carrier protein using (19)F-NMR. 2013 Apr 1
24 23488865 Latest advances in the discovery of fatty acid amide hydrolase inhibitors. 2013 May 2
25 26588763 Wagging the Tail: Essential Role of Substrate Flexibility in FAAH Catalysis. 2013 Feb 12 1
26 22473870 Contribution of genetic variants to pain susceptibility in Parkinson disease. 2012 Oct 1
27 21477106 Association of genetic variation in cannabinoid mechanisms and gastric motor functions and satiation in overweight and obesity. 2011 Jul 1
28 20022504 Synthesis and biological evaluation of new potential inhibitors of N-acylethanolamine hydrolyzing acid amidase. 2010 Feb 1 1
29 20152858 N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA). 2010 Oct 1
30 18289091 Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors. 2008 2
31 18753625 Structure-guided inhibitor design for human FAAH by interspecies active site conversion. 2008 Sep 2 1
32 18851692 The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets. 2008 Nov 1
33 17158103 Closing the gate to the active site: effect of the inhibitor methoxyarachidonyl fluorophosphonate on the conformation and membrane binding of fatty acid amide hydrolase. 2007 Feb 9 1
34 16392827 Substituted 2-thioxoimidazolidin-4-ones and imidazolidine-2,4-diones as fatty acid amide hydrolase inhibitors templates. 2006 Jan 12 1
35 16892344 Synthesis and structure-activity relationships of FAAH inhibitors: cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring. 2006 Jan 1
36 17015445 A second fatty acid amide hydrolase with variable distribution among placental mammals. 2006 Dec 1 1
37 15533037 Assignment of endogenous substrates to enzymes by global metabolite profiling. 2004 Nov 16 1
38 23409303 6-Hydroxy-[1,1'-biphenyl]-3-yl-cyclohexyl-[11C-carbonyl]carbamate 2004 1
39 11585048 Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide. 2001 Sep 1 1